

81
Please insert the following in the first sentence of the application -- This application is a continuation of U.S. application no. 08/377, 798, filed January 24, 1995, now abandoned, which is a continuation-in-part of U.S. application no. 08/253,663, filed May 3, 1995, now abandoned.-

IN THE CLAIMS:

Please cancel claims 1-24, 28-30, 35-38, 40, 42-70 and 75 without prejudice.

82
71. A method for treating or inhibiting atherosclerosis in a mammal comprising:
providing an agent for inhibiting an interaction between P-selectin and a ligand of P-selectin and between E-selectin and a ligand of E-selectin; and
administering said agent to a mammal in need of such treatment so as to cause such inhibition to occur, wherein said agent is selected from the group consisting of PSGL-1, soluble forms of PSGL-1, fragments of PSGL-1, and mimetics of PSGL-1.

72. The method of claim 71 wherein said P-selectin is on a cell.

73. The method of claim 72 wherein said cell is an endothelial cell.

74. The method of claim 71 wherein said ligand of P-selectin comprises a glycoprotein.

76. The method of claim 71 wherein said ligand of P-selectin is selected from the group consisting of sialyl-Lewis x, sialyl-Lewis a, sialyl-Lewis-x-pentasaccharide, polyactosaminoglean, carbohydrate containing 2,6 sialic acid, Lewis x 3'-0-sulfate, heparin oligosaccharides, PSGL-1, 160 kD monospecific P-selectin ligand and lysosomal membrane glycoproteins.

77. The method of claim 71 wherein said ligand of P-selectin is on a cell, selected from the group consisting of monocytes, neutrophils, eosinophils, CD+4 T cells, CD+8 T cells, and natural killer cells.

